GSK1265744 30mg + Placebo + GSK1265744 5mg

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infection, Human Immunodeficiency Virus

Conditions

Infection, Human Immunodeficiency Virus

Trial Timeline

Jun 9, 2009 → Aug 13, 2009

About GSK1265744 30mg + Placebo + GSK1265744 5mg

GSK1265744 30mg + Placebo + GSK1265744 5mg is a phase 2 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT00920426. Target conditions include Infection, Human Immunodeficiency Virus.

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00920426Phase 2Completed

Competing Products

20 competing products in Infection, Human Immunodeficiency Virus

See all competitors
ProductCompanyStageHype Score
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1944ModernaPhase 1
0
mRNA-1189ModernaPhase 2
0
mRNA-1647ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0
mRNA-1195.1ModernaPhase 1
0
mRNA-1647ModernaPhase 1
0
mRNA-1647ModernaPhase 3
0
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
BSG005Alkem LaboratoriesPhase 1/2
39
Zotatifin + PlaceboeFFECTOR TherapeuticsPhase 1
19
AAVLP-HPV + Placebo2A PharmaPhase 1
19
CT-P59CelltrionPhase 1
29
CT-P63 + PlaceboCelltrionPhase 1
29